XNYS · Drug Manufacturers - General
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$63.06+0.35%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
68/100
Positive
Score components
TickerWhale View
Bristol-Myers Squibb Company scores 68 out of 100 overall, which we rate positive. Valuation is its strongest area and Risk its weakest.
What helps
- Technical
- Valuation
- Sentiment Signal
What to watch
- Quality & growth
- Risk
Quality & growth
30%47Moderate
- Revenue growth 3.1%
- EPS growth 83.1%
Valuation
25%95Strong
- P/E 13.9
- EV/Sales 3.3
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
#95 by market cap in our coverage · ~32,500 employees · Listed 1952-06-23 · www.bms.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#17 / 139sector rank by TickerWhale Score
TickerWhale Score 68 vs sector average 55.1 (+12.9)
Revenue growth (industry)Top 73%
Gross margin (industry)Top 73%
Return on equity (industry)Top 30%
P/E (industry)Cheaper than 100%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
84/100Strong vs universe
Ranks 84th of 100 covered names on our technical composite — the composite itself scores 66/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
2 buy · 4 sell · 2 neutral of 8 votes
TickerWhale rates BMY's technical setup strong — 84th percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
3 / 9constructive
- vs 200-day+7.1%
- vs 50-day-1.5%
Momentum
Mixed
- RSI (14)41 · neutral
- Stochasticbuy
- CCIsell
- Williams %Rbuy
Trend
Mixed
- ADX (14) trend strength17· weak trend
- MACD (12,26,9)sell(histogram -0.539)
How the classic verdict is reached
Moving averages (9) agree on sell — 3 buy vs 6 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 3 sell · 2 neutral.
Result — 2 buy vs 4 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)13.9
- P/S (TTM)2.6
- P/B5.8
- EV/EBITDA—
- EV/Sales3.3
- PEG—
Profitability & returns
- Gross margin70.2%
- Net margin18.9%
- ROE43.8%
- Debt/Equity1.93
Growth
- Revenue growth (YoY)3.1%
- EPS growth (YoY)83.1%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $129.1B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $48.2B | $48.3B | $45.0B |
| Gross profit | $34.3B | $34.3B | $34.3B |
| Operating income | $9.3B | -$8.4B | $8.4B |
| Net income | $7.1B | -$8.9B | $8.0B |
| EPS (diluted) | $3.46 | $-4.41 | $3.86 |
| Free cash flow | $12.8B | $13.9B | $12.7B |
| Cash | $10.2B | $10.3B | $11.5B |
| Total debt | $45.1B | $49.6B | $39.8B |
| Equity | $18.5B | $16.3B | $29.4B |
| Net debt | $34.9B | $39.3B | $28.3B |
| Debt / equity | 2.44 | 3.04 | 1.35 |
| Liabilities / assets | 0.79 | 0.82 | 0.69 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BMYCurrentBristol-Myers Squibb Company | 68 | 66 | 13.9 | — | 5.8 | 3.3 | $63.06 | +0.35% | +3.1% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.